Clinical Scenario 1: Young Patient with EGFR-Mutant NSCLC Showing High-Risk Features

A 50-year-old never-smoker presents with stage IV disease involving bone and contralateral lung metastases, excellent performance status, and molecular testing revealing EGFR exon 19 deletion with concurrent TP53 R175H mutation. The patient is employed with strong social support and reliable transportation.

Dr. Olazagasti notes that although exon 19 deletions historically showed superior outcomes compared to L858R mutations, cure remains elusive even with targeted therapy. The TP53 mutation elevates this patient's risk profile, mandating combination therapy consideration rather than debating the need for intensification.

The treatment discussion focuses on regimen selection rather than monotherapy versus combination approaches. FLAURA2 requires whole-day clinic visits every 3 weeks throughout most of the first year, potentially affecting work schedules significantly. Patients essentially commit to intensive treatment schedules for 7 to 8 months before potential treatment modifications.

The MARIPOSA alternative offers a chemotherapy-free bispecific antibody approach with subcutaneous administration, eliminating nausea and reducing infusion center time. However, patients must commit to intensive skin management during the first 4 months, including 3 daily prescriptions: oral antibiotics, topical treatments, and anticoagulation.

Dr. Rodriguez introduces the concept of visible versus invisible treatment regimens. Chemotherapy may cause fatigue and work limitations but allows patients to "go undercover" without obvious treatment-related appearance changes. Conversely, amivantamab may cause visible skin toxicity requiring patient discussions with family and colleagues about their treatment status.

For motivated young patients willing to be proactive about treatment management, the potential benefits of MARIPOSA, including possible resistance pattern modifications and superior CNS activity, may outweigh intensive management requirements during the initial treatment period.